Tag: Roche’s Tecentriq-chemotherapy combo now approved for treating aggressive type of lung cancer

Roche’s Tecentriq-chemotherapy combo now approved for treating aggressive type of lung cancer

May 21, 2020

The Singaporean Health Sciences Authority (HAS) has recently approved of global pharmaceutical giant Roche’s new immunotherapy treatment: Tecentriq® (Atezolizumab) will be used as first-line treatment of adults with extensive-stage small cell lung cancer (ES-SCLC), after reports showed that the cancer immunotherapy helped patients live significantly longer compared to chemotherapy alone. Apart from Singapore, the immunotherapy […]

Continue Reading